NCT01700257

Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Different Strategies Using Autoantibodies and/or CT Scan Detection of Lung Cancer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,361 (actual)
• Sponsor: National Jewish Health · Academic / Other
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Detailed description

In this trial, the addition of a blood biomarker test is being combined with early LDCT to determine if screening with combination may result in detection of more lung cancer at an earlier stage of disease.The study will also assess if the blood test is able to detect lung cancers in high risk individuals when the LDCT is negative for cancer. There will be health-economic costs included in the final analysis of study data.

Conditions

• High Risk of Developing Lung Cancer

Interventions

Type	Name	Description
RADIATION	CT scan & Early CDT Lung test
OTHER	CT scan & Early CDT Lung test

Timeline

• Start date: 2012-05-01
• Primary completion: 2020-12-07
• Completion: 2020-12-07
• First posted: 2012-10-04
• Last updated: 2020-12-31

Locations

1 site across 1 country: United States